The DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index.
Caspase-cleavage of tau is an early event in Alzheimer disease tangle pathology
Open accessAbstract
Neurofibrillary tangles (NFTs) are composed of abnormal aggregates of the cytoskeletal protein tau. Together with amyloid β (Aβ) plaques and neuronal and synaptic loss, NFTs constitute the primary pathological hallmarks of Alzheimer disease (AD). Recent evidence also suggests that caspases are activated early in the progression of AD and may play a role in neuronal loss and NFT pathology. Here we demonstrate that tau is cleaved at D421 (ΔTau) by executioner caspases. Following caspase-cleavage, ΔTau facilitates nucleation-dependent filament formation and readily adopts a conformational change recognized by the early pathological tau marker MC1. ΔTau can be phosphorylated by glycogen synthase kinase-3β and subsequently recognized by the NFT antibody PHF-1. In transgenic mice and AD brains, ΔTau associates with both early and late markers of NFTs and is correlated with cognitive decline. Additionally, ΔTau colocalizes with Aβ1–42 and is induced by Aβ1–42 in vitro. Collectively, our data imply that Aβ accumulation triggers caspase activation, leading to caspase-cleavage of tau, and that this is an early event that may precede hyperphosphorylation in the evolution of AD tangle pathology. These results suggest that therapeutics aimed at inhibiting tau caspase-cleavage may prove beneficial not only in preventing NFT formation, but also in slowing cognitive decline.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This is consistent with the observation that C-terminal truncated forms of Tau show increased polymerization capacity in vitro and are associated with NFTs formation in the brain of AD patients (Gamblin et al., 2003; Rissman et al., 2004).”
From Emerging Alternative Proteinases in APP Metabolism and Alzheimer’s Disease Pathogenesis: A Focus on MT1-MMP and MT5-MMP (2019) · cites this paper as Rissman et al., 2004
In the citing paper
“Δtau levels were below the detectable level in our 7-month-old, untreated 3xTg-AD mice”
From The mitochondria-targeted antioxidant MitoQ prevents loss of spatial memory retention and early neuropathology in a transgenic mouse model of Alzheimer’s disease (2011) · cites this paper as Rissman et al., 2004
In the citing paper
“Recent evidence suggests that executioner caspases 3 and 7 may contribute to tau, the protein responsible for forming NFTs, pathology by cleaving tau after Asp421 to yield a cytotoxic Δtau fragment (Rissman et al., 2004; Rohn et al., 2008; de Calignon et al., 2010).”
From The mitochondria-targeted antioxidant MitoQ prevents loss of spatial memory retention and early neuropathology in a transgenic mouse model of Alzheimer’s disease (2011) · cites this paper as Rissman et al., 2004
In the citing paper
“only caspase-2, 3 and 6 cleaved tau products have been linked to AD [190–193].”
From Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease (2020) · cites this paper as [192]
In the citing paper
“Although tau can be cleaved by caspase-1, 2, 3, 6 and 7 in vitro”
From Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease (2020) · cites this paper as [192]
In the citing paper
“Tau-421 colocalizes with NFTs in human AD brain, and correlates with NFT formation and cognitive impairment in aged mice [191, 192, 194].”
From Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease (2020) · cites this paper as [192]
In the citing paper
“Elevated levels of caspase-3 and tau-421 have been observed in AD, as well as PSP [130, 191, 192].”
From Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease (2020) · cites this paper as [192]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Apoptosis: A Basic Biological Phenomenon with Wideranging Implications in Tissue Kinetics
Kerr, J. F. R., Wyllie, A. H., & Currie, A. R. (1972) · British Journal of Cancer · doi:10.1038/bjc.1972.33 · Cited by 15,673
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Mild Cognitive Impairment: Clinical Characterization and Outcome
Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Tangalos, E. G., & Kokmen, E. (1999) · Archives of Neurology · doi:10.1001/archneur.56.3.303 · Cited by 8,980
Triple-Transgenic Model of Alzheimer’s Disease with Plaques and Tangles
Oddo, S., Caccamo, A., Shepherd, J. D., Murphy, M. P., Golde, T. E., Kayed, R., Metherate, R., Mattson, M. P., Akbari, Y., & LaFerla, F. M. (2003) · Neuron · doi:10.1016/s0896-6273(03)00434-3 · Cited by 4,126
Self-citationLee, V. M.-Y., Goedert, M., & Trojanowski, J. Q. (2001) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.24.1.1121 · Cited by 2,480
Buée, L., Bussière, T., Buée‐Scherrer, V., Delacourte, A., & Hof, P. R. (2000) · Brain Research Reviews · doi:10.1016/s0165-0173(00)00019-9 · Cited by 2,142
Microtubule-associated protein tau. A component of Alzheimer paired helical filaments.
Grundke, I., Iqbal, K., Quinlan, M., Tung, Y. C., Zaidi, M. S., & Wisniewski, H. M. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)38495-8 · Cited by 1,780
Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP
Lewis, J., Dickson, D. W., Lin, W.-L., Chisholm, L., Corral, A., Jones, G., Yen, S.-H., Sahara, N., Skipper, L., Yager, D., et al. (2001) · Science · doi:10.1126/science.1058189 · Cited by 1,611
Formation of Neurofibrillary Tangles in P301L Tau Transgenic Mice Induced by Aβ42 Fibrils
Götz, J., Chen, F., van Dorpe, J., & Nitsch, R. M. (2001) · Science · doi:10.1126/science.1062097 · Cited by 1,526
Flagged first, then by citations
Research works printed but not linked: 1
- Yang, 1998, Am. J. Pathol., 152, 379
Cited by
Sorted by citations
Items 401–500 of 544
Datta, D., & Arnsten, A. F. T. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14477 · Cited by 11
Retromer deficiency in Tauopathy models enhances the truncation and toxicity of Tau
Asadzadeh, J., Ruchti, E., Jiao, W., Limoni, G., MacLachlan, C., Small, S. A., Knott, G., Santa-Maria, I., & McCabe, B. D. (2022) · Nature Communications · doi:10.1038/s41467-022-32683-5 · Cited by 14
Mahady, L. J., Perez, S. E., Malek‐Ahmadi, M. H., & Mufson, E. J. (2023) · The Journal of Comparative Neurology · doi:10.1002/cne.25466 · Cited by 11
Katow, H., Kanaya, T., Ogawa, T., Egawa, R., & Yawo, H. (2017) · Development Growth & Differentiation · doi:10.1111/dgd.12346 · Cited by 11
Yoon, S. C., Kwon, Y.-A., Kim, H. R., Kim, S., Jo, S. A., & Kim, D. K. (2010) · Psychiatry Investigation · doi:10.4306/pi.2010.7.1.68 · Cited by 11
Gene-environment interplay in neurogenesis and neurodegeneration
Palomo, T., Archer, T., Beninger, R. J., & Kostrzewa, R. M. (2004) · Neurotoxicity Research · doi:10.1007/bf03033279 · Cited by 11
Validation of Tau Antibodies for Use in Western Blotting and ImmunohistochemistryPreprint
Ellis, M. J., Lekka, C., Tulmin, H., O'Brien, D. P., Dhayal, S., Zeissler, M., Knudsen, J. G., Kessler, B. M., Morgan, N. G., Todd, J. A., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.04.13.536711 · Cited by 15
Behroozi, Z., Askarpour, H., & Baghcheghi, Y. (2026) · Journal of Alzheimer s Disease Reports · doi:10.1177/25424823261415807 · Cited by 10
Targeting Glucocorticoid Receptors: A New Avenue for Alzheimer’s Disease Therapy
Canet, G., Chevallier, N., Perrier, V., Desrumaux, C. M., & Givalois, L. (2018) · Springer eBooks · doi:10.1007/978-981-13-0944-1_15 · Cited by 10
Mutant three-repeat tau expression initiates retinal ganglion cell death through Caspase-2
Ngolab, J., Canchi, S., Rasool, S., El-Maarouf, A., Thomas, K., Sarsoza, F. M., Grundman, J., Mante, M., Florio, J. B., Nandankar, N., et al. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2021.105277 · Cited by 10
Self-citationHyperosmotic Stress Induces Tau Proteolysis by Caspase‐3 Activation in SH‐SY5Y Cells
Catalina, M. O., Bermejo, M. C., Argent, R., Alonso, J. C., Cuenda, A., Lorenzo, M. J. V., & Centeno, F. (2016) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25579 · Cited by 10
Goswami, S., Kareem, O., Goyal, R. K., Mumtaz, S. M., Tonk, R. K., Gupta, R., & Pottoo, F. H. (2020) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527319666201001105553 · Cited by 10
Chauhan, P., Wadhwa, K., & Singh, G. (2025) · Pathology - Research and Practice · doi:10.1016/j.prp.2025.156109 · Cited by 12
Caspases: A Potential Therapeutic Targets in the Treatment of Alzheimer’s Disease
Jana, K. (2013) · Translational Medicine · doi:10.4172/2161-1025.s2-006 · Cited by 9
Cicconi, S., Gentile, A., Ciotti, M. T., Parasassi, T., Serafino, A., & Calissano, P. (2007) · Journal of Alzheimer s Disease · doi:10.3233/jad-2007-12301 · Cited by 8
Kumasaka, D. K., Galván, V., Head, E., & Rohn, T. T. (2009) · PubMed Central · Cited by 9
Self-citationG1/S Cell Cycle Checkpoint Defect in Lymphocytes from Patients with Alzheimer's Disease
Song, M., Kwon, Y.-A., Lee, Y., Kim, H. R., Yun, J. H., Kim, S., & Kim, D. K. (2012) · Psychiatry Investigation · doi:10.4306/pi.2012.9.4.413 · Cited by 9
Heterogeneous Dynamics of the Fuzzy Coat of Full-Length Phospho-Mimetic Tau Fibrils
Zhang, J. Y., Dregni, A. J., & Hong, M. (2026) · Journal of the American Chemical Society · doi:10.1021/jacs.5c18540 · Cited by 8
Novel molecular mechanisms in Alzheimer’s disease: The potential role of DEK in disease pathogenesis
Greene, A. N., Solomon, M. B., & Vinnedge, L. M. P. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.1018180 · Cited by 8
Bossolasco, P., Cimini, S., Maderna, E., Bardelli, D., Canafoglia, L., Cavallaro, T., Ricci, M., Silani, V., Marucci, G., & Rossi, G. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105891 · Cited by 8
Elia, A., Parodi‐Rullán, R. M., Vázquez‐Torres, R., Carey, A. M., Zhao, H., Javadov, S. A., & Fossati, S. (2026) · Advanced Science · doi:10.1002/advs.202511924 · Cited by 9
The Role of Aβ and Tau Oligomers in the Pathogenesis of Alzheimer’s Disease
Bhaskar, K., & Lamb, B. T. (2011) · Springer eBooks · doi:10.1007/978-94-007-2774-8_5 · Cited by 8
Afreen, S., & Ferreira, A. (2019) · Neuroscience · doi:10.1016/j.neuroscience.2019.05.046 · Cited by 8
Caspase-2 and tau—a toxic partnership?
Troy, C. M., & Shelanski, M. L. (2016) · Nature Medicine · doi:10.1038/nm.4227 · Cited by 10
Neurobiological Mechanisms Involved in the Pathogenesis of Alzheimer’s Disease
Mir, F. A., & Rizvi, Z. A. (2019) · Springer eBooks · doi:10.1007/978-981-13-9636-6_13 · Cited by 8
Checler, F., & Buée, L. (2009) · Annales Pharmaceutiques Françaises · doi:10.1016/j.pharma.2009.01.002 · Cited by 12
Zhang, K.-X., Zhang, J., Jiang, Y.-H., Wang, Y., Liu, Z., Ding, P., Wang, X., Cui, W., Xu, X., & Wang, Y. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s490900 · Cited by 7
Neuschmid, S., Schallerer, C., Ehrlich, B. E., & McGuone, D. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26189245 · Cited by 8
Horta‐López, P. H., Mendoza-Franco, G., Rodríguez‐Cruz, F., Torres-Cruz, F. M., Hernández, E., Jarero-Basulto, J. J., Říčný, J., Florán, B., & García‐Sierra, F. (2022) · Neuroscience · doi:10.1016/j.neuroscience.2022.01.002 · Cited by 7
Regulation of tau proteolysis by phosphatases
Lee, S., & Shea, T. B. (2012) · Brain Research · doi:10.1016/j.brainres.2012.10.023 · Cited by 7
Muraoka, S., DeLeo, A. M., Sethi, M. K., Takamatsu-Yukawa, K., Yang, Z., Ko, J., Hogan, J., Ruan, Z., You, Y., Wang, Y., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/733477 · Cited by 7
Theofilas, P., Wang, C., Butler, D., Morales, D. O., Petersen, C., Ambrose, A. J., Chin, B., Yang, T. T. C., Khan, S., Ng, R. A., et al. (2021) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2024.103954 · Cited by 6
Olesen, M. A., Villavicencio-Tejo, F., Johnson, G. V. W., Porter, G. A., & Quintanilla, R. A. (2025) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2025.02.035 · Cited by 6
Dual truncation of tau by caspase-2 accelerates its CHIP-mediated degradation
Reinhardt, L., Musacchio, F., Bichmann, M., Behrendt, A., Ercan-Herbst, E., Stein, J., Becher, I., Haberkant, P., Mader, J. K., Schöndorf, D. C., et al. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106126 · Cited by 6
Bodelón, M. N., Santpere, G., Torrejón-Escribano, B., Puig, B., & Ferrer, I. (2006) · Acta Neuropathologica · doi:10.1007/s00401-005-0013-0 · Cited by 6
Methods related to studying tau fragmentation
Ferreira, A., & Afreen, S. (2017) · Methods in cell biology · doi:10.1016/bs.mcb.2017.06.004 · Cited by 6
Theofilas, P., Ambrose, A. J., Butler, D., Wang, C., Morales, D. O., Petersen, C., Chin, B., Yang, T. T. C., Khan, S., Ng, R. A., et al. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.051471 · Cited by 6
Steroids and Brain, a Rising Bio-Medical Domain: a Perspective
Baulieu, É.-É. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00316 · Cited by 6
Molecular Mechanisms of Neuronal Death
Ribé, E. M., Heidt, L., Beaubier, N. T., & Troy, C. M. (2010) · Advances in neurobiology · doi:10.1007/978-1-4419-7104-3_2 · Cited by 6
Baghel, M. S., Burns, G. D., Tsapatsis, M., Mallika, A. P., Cruz, A. L., Cao, T., Chen, X. K., Rosa, I. D. L., Marx, S. R., Ye, Y., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.06.26.600814 · Cited by 6
Weidling, I. W., Preiss, C. N., Chancellor, S. E., Srivastava, G. P., Gibilisco, L., Lin, G., Brennan, M. S., Lee, J. Y., Roth, L. M., Morozova, O., et al. (2025) · Acta Neuropathologica Communications · doi:10.1186/s40478-025-02000-4 · Cited by 5
Palomares, D., Vanparys, A., Jorgji, J., Paître, E., Kienlen‐Campard, P., & Suelves, N. (2025) · Acta Neuropathologica Communications · doi:10.1186/s40478-025-02118-5 · Cited by 7
Tau and neurodegenerative disorders
Motoi, Y., Sahara, N., Kambe, T., & Hattori, N. (2010) · BioMolecular Concepts · doi:10.1515/bmc.2010.017 · Cited by 5
Clinical & Experimental Pathology
Ren, R., Fedoriw, Y. D., & Willis, M. S. (2012) · Cited by 5
New application of β‐galactosidase complementation to monitor tau self‐association
Ding, H., & Johnson, G. V. W. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05496.x · Cited by 5
FTLD-MAPT mutations and short 5′UTR Tau mRNAs increase Tau translation
da Costa, P. J., Perret, A., Buée, L., Hamdane, M., & Martin, F. (2024) · NAR Molecular Medicine · doi:10.1093/narmme/ugae023 · Cited by 4
Hwang, I. K., Ahn, J. H., Yoo, D. Y., Lee, C. H., Yoo, K., Choi, J. H., Moon, S. M., Shin, H., & Won, M. (2011) · Neurochemical Research · doi:10.1007/s11064-011-0633-9 · Cited by 4
Caspase Cleaved Tau in Alzheimer's Disease: A Therapeutic Target Realized
Rohn, T. T. (2015) · International Journal of Neurology and Neurotherapy · doi:10.23937/2378-3001/2/1/1014 · Cited by 4
Self-citationChi, H., Sang, T., & Chang, H.-Y. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.73198 · Cited by 5
Khabiya, R., Karati, D., Dwivedi, S., Dwivedi, A., & Mukherjee, S. (2024) · Brain Disorders · doi:10.1016/j.dscb.2024.100125 · Cited by 4
Molecular Aspects of Memory Dysfunction in Alzheimer’s Disease
Chin, J., Roberson, E. D., & Mucke, L. (2008) · Elsevier eBooks · doi:10.1016/b978-012370509-9.00015-2 · Cited by 5
Naturally occurring Alzheimer’s disease in rhesus monkeysPreprint
Li, Z., He, X., Wu, S., Huang, R., Li, H., Wang, Z., Wang, L., Qin, D., Kong, Y., Guo, Y., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.10.20.513120 · Cited by 5
Structures of ΔD421 Truncated Tau Fibrils
Mammeri, N. E., Duan, P., & Hong, M. (2025) · Journal of Molecular Biology · doi:10.1016/j.jmb.2025.169051 · Cited by 3
Is tau pathology a relevant factor in neuronal damage induced by alcohol and other drugs?
Olesen, M. A., Ancía, A., & Quintanilla, R. A. (2025) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2025.168059 · Cited by 3
Molecular Pathways in Alzheimer’s Disease and Cognitive Function
Chen, X., Reichert, M. C., & Gan, L. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802851-3.00005-x · Cited by 3
Inflammasome-Mediated Inflammation in Neurodegenerative Diseases
Park, J. Y., Kang, Y. W., & Cho, W. G. (2019) · The Open Neurology Journal · doi:10.2174/1874205x01913010055 · Cited by 3
Calcium Induces Expression of Cytoplasmic Gelsolin in SH-SY5Y and HEK-293 Cells
Ji, L., Chauhan, A., & Chauhan, V. P. S. (2010) · Neurochemical Research · doi:10.1007/s11064-010-0157-8 · Cited by 3
Axelsen, T. M., Bager, C. L., Bihlet, A. R., Karsdal, M. A., Henriksen, K., & Tang, M. E. (2023) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2023.36 · Cited by 3
Méduri, G., Guillemeau, K., Daguinot, C., Dounane, O., Genet, M., Ferrara, L., Chambraud, B., Baulieu, E. E., & Giustiniani, J. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230127 · Cited by 3
Neurochemical Aspects of Alzheimer Disease
Farooqui, A. A. (2016) · Springer eBooks · doi:10.1007/978-3-319-15889-1_1 · Cited by 2
Application of the Movable Type Free Energy Method to the Caspase-Inhibitor Binding Affinity Study
Xue, S., Liu, H., & Zheng, Z. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20194850 · Cited by 2
FAIM-L - SIVA-1: Two Modulators of XIAP in Non-Apoptotic Caspase Function
Coccia, E., Solé, M., & Comella, J. X. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.826037 · Cited by 2
Deep Trans-Omic Network Fusion for Molecular Mechanism of Alzheimer’s Disease
Xie, L., Raj, Y., Varathan, P., He, B., Yu, M., Nho, K., Salama, P., Saykin, A. J., & Yan, J. (2024) · Journal of Alzheimer's Disease · doi:10.3233/jad-240098 · Cited by 2
Kása, P., Papp, H., Beke, Z., Vadász, D., & Zombori, J. (2004) · Acta Biologica Szegediensis · Cited by 2
PGCLCs of human 45,XO reveal pathogenetic pathways of neurocognitive and psychosocial disorders
Shang, D., Lan, T., Wang, Y., Li, X., Liu, Q., Dong, H., Xu, B., Cheng, H., & Zhou, R. (2022) · Cell & Bioscience · doi:10.1186/s13578-022-00925-0 · Cited by 2
Mondragón‐Rodríguez, S., Perry, G. L., & Peña‐Ortega, F. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802810-0.00008-8 · Cited by 2
Salles, M. B. (2007) · doi:10.11606/t.42.2007.tde-28012008-100634 · Cited by 2
The Principal Inferior Olivary Nucleus in Aging and Alzheimer's Disease
Lasn, H. (2006) · Figshare · Cited by 2
Sahu, K. K., Chaudhary, R., Farooqi, M. A., & Kaurav, M. (2024) · Drug Delivery Letters · doi:10.2174/0122103031331346241122152643 · Cited by 1
Exploring Tau-C, Tau-A, and C1M as biomarkers for Parkinson’s disease
Benmarce, M., Henriksen, K., Karsdal, M. A., & Nielsen, S. H. (2025) · Frontiers in Neurology · doi:10.3389/fneur.2025.1566228 · Cited by 1
Garrahy, J. P. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251404970 · Cited by 1
Datta, D., Wang, M., & Arnsten, A. F. T. (2026) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2026.1750092 · Cited by 1
Guedjdal, S., Leghay, C., Derisbourg, M. J., Eddarkaoui, S., Lecerf, S., Vermon, F., Caillierez, R., Bégard, S., Regost, C., Laloux, C., et al. (2026) · Translational Neurodegeneration · doi:10.1186/s40035-026-00550-8 · Cited by 2
García‐Sierra, F., Basurto‐Islas, G., Jarero-Basulto, J., Hugo, C., Cruz, F. M. T., Cortés, H., Rojas, H., Krištofíková, Z., Řı́pová, D., Luna‐Muñoz, J., et al. (2011) · InTech eBooks · doi:10.5772/17077 · Cited by 2
Biomarkers in Alzheimer's Disease and Lewy Body Disorders with Dementia
Leyhe, T., Darreh‐Shori, T., Laske, C., Mielke, M. M., & Maetzler, W. (2013) · International Journal of Alzheimer s Disease · doi:10.1155/2013/473181 · Cited by 1
Molecular Mechanism Underlying Aβ Immunotherapy: Implications for the Toxic Action of Aβ Oligomers
Matsubara, E. (2013) · Journal of Gerontology & Geriatric Research · doi:10.4172/2167-7182.s2-001 · Cited by 1
A Model of the Role of Cholesterol in the Development of Alzheimer’s Disease
Vianna, G. K., Reis, A. E. S., de Carvalho, L. A. V., & Wedemann, R. S. (2006) · Lecture notes in computer science · doi:10.1007/11758501_119 · Cited by 1
Carola Otth, L., Leyton, L., Salamin, M., Acuña, F., Martín, C., & Concha, M. I. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160508 · Cited by 1
Current and Future Therapies for Alzheimer Disease
Chakrabarty, P., Das, P., & Golde, T. E. (2010) · Wiley eBooks · doi:10.1002/9780470572702.ch34 · Cited by 1
Ronayne, R. E. (2008) · Digital WPI · Cited by 1
Chemoproteomics identifies proteoform-selective caspase-2 inhibitorsPreprint
Castellón, J. O., Ofori, S., Armenta, E., Burton, N. R., Boatner, L. M., Takayoshi, E. E., Faragalla, M., Zhou, A., Tran, K., Shek, J., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.10.25.563785 · Cited by 1
Incorporation of Other Biomarkers
Gnanapavan, S., & Giovannoni, G. (2008) · Springer eBooks · doi:10.1007/978-88-470-0391-0_15
Waldmeier, P. C. (2007) · Elsevier eBooks · doi:10.1016/b978-044452809-4/50162-9
González, M. C. (2013) · Gredos (University of Salamanca) · doi:10.14201/gredos.122909
Conformation of Human Microtubule Associated Protein-Tau
Jeganathan�, S. (2008) · Max Planck Institute for Plasma Physics
Vianna, G. K., Reis, A. E. S., & de Carvalho, L. A. V. (2007) · Summer Computer Simulation Conference · doi:10.5555/1357910.1358031
Factors patogènics convergents en taupaties
Santpere, G. (2009) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Farooqui, A. A. (2008) · Springer eBooks · doi:10.1007/978-0-387-09693-3_10
Murtishaw, A. S. (2020) · Digital Scholarship - UNLV (University of Nevada Reno) · doi:10.34917/6456429
Introspective Analysis of Amyloid as the Cause of Alzheimer‘s Disease: Alternative Model Proposed
LeBlanc, A. C. (2008) · Future Neurology · doi:10.2217/14796708.3.5.527
Aβ-Induced Toxicity Mediated by Caspase Cleavage of the Amyloid Precursor Protein (APP)
Koo, E. H., & Bredesen, D. E. (2008) · Research and perspectives in Alzheimer's disease · doi:10.1007/978-3-540-76330-7_11
Molecular changes during the development of Alzheimer's disease
Wirz, K. T. S. (2013) · Data Archiving and Networked Services (DANS)
Mouse and stem cell models of frontotemporal dementia
Orr, M. E. (2012) · Montana State University ScholarWorks (Montana State University)
Rohn, T. T., Kokoulina, P., Eaton, C. R., & Poon, W. W. (2009)
Self-citationTau Pathology: A Selected View on the Current Status
Gozes, I. (2012) · Advances in predictive, preventive and personalised medicine · doi:10.1007/978-94-007-5866-7_5
Animal Models in Neuro Ophthalmology
Normando, E. M., Brodie, J. T., & Cordeiro, M. F. (2016) · Springer eBooks · doi:10.1007/978-3-319-24085-5_13
Dickey, C., & Clark, K. P. (2006)
Butzlaff, M. (2011) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-1007
Metadata
- Authors
- Rissman, R. A., Poon, W. W., Blurton-Jones, M., Oddo, S., Torp, R., Vitek, M. P., LaFerla, F. M., Rohn, T. T., & Cotman, C. W.
- Affiliations
- University of California, Irvine (US)
- Duke Medical Center (US)
- Boise State University (US)
- Corresponding author
- Cotman, Carl W.
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2004-07-01
- Volume
- 114
- Issue
- 1
- Pages
- 121-130
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC437967
- OpenAlex
- W1989856924
- Cited by
- 543
- References
- 82
- Citations by year
- 2026: 10 · 2025: 20 · 2024: 20 · 2023: 20 · 2022: 20 · 2021: 23 · 2020: 32 · 2019: 28 · 2018: 33 · 2017: 24 · 2016: 30 · 2015: 26 · 2014: 19 · 2013: 27 · 2012: 30
- FWCI
- 13.40
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- ScholarWorks (Boise State University) (submittedVersion)
- Funders
- National Institutes of Health (1r03ag019386-01, AG016573, AG000096, AG000538)
- National Institute on Aging (P01AG000538, AG19386, AG19780, AG-000538, AG17968, AG000096, R01AG017968, P50AG016573, F32AG023433, AG023433, R01AG019780, T32AG000096)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- tau cleavage, caspase activation, neurofibrillary tangles, Alzheimer's disease, amyloid-beta, glycogen synthase kinase-3β, tau phosphorylation, PHF1, cognitive decline, mild cognitive impairment, traumatic brain injury, triple transgenic mouse model
- MeSH terms
- Alzheimer Disease, Animals, Humans, Membrane Proteins, Mice, Transgenic, Phosphorylation, Reference Values, Neurofibrillary Tangles, tau Proteins, Pyramidal Cells, Mice, Knockout, Caspases, Mice, Presenilin-1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
